title: Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
abstract: BACKGROUND
  Cytochrome P450 2C19 (CYP2C19) polymorphism has been associated with the development of lung, liver or oesophageal cancer by detoxification of carcinogen(s) or activation of procarcinogen(s).
  
  
  OBJECTIVE
  To clarify the association between CYP2C19 polymorphisms and gastric cancer development in Japanese. Methods : We determined CYP2C19 genotypes (CYP2C19*1, *2 and *3) in 111 Helicobacter pylori-positive patients with gastric cancer and 315 H. pylori-positive controls without gastric cancer consisting of patients with gastritis only or peptic ulcer. Frequencies of CYP2C19 genotypes and serum pepsinogen I and II levels, a biomarker of gastric atrophy, in the gastric cancers and controls were compared.
  
  
  RESULTS
  Frequencies of homozygous extensive metabolizers, heterozygous extensive metabolizers and poor metabolizers were 31.5%, 42.3% and 26.2% in the gastric cancers and 38.1%, 47.0% and 14.9% in the controls, respectively (P = 0.046). Poor metabolizers were associated with an increased risk for developing gastric cancer with the age- and sex-adjusted odds ratio (OR) of 1.975 [95% confidence interval (CI): 1.068-3.649], especially for diffuse type (OR: 3.385, CI: 1.187-9.648). There is no significant association between CYP2C19 genotypes and serum pepsinogen I level or pepsinogen I/II ratios, although serum pepsinogen I level in gastric cancers were significantly decreased.
  
  
  CONCLUSIONS
  In H. pylori-positive Japanese, poor metabolizers of CYP2C19 appear to be at an increased risk for developing gastric cancer, especially diffuse type, and may require an intensive follow-up for scrutinizing possible gastric cancer development.
authors.affiliation: First Department of Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan. mitsu@hama-med.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Sugimoto
authors.forename: T
authors.initials: T
authors.lastname: Furuta
authors.forename: N
authors.initials: N
authors.lastname: Shirai
authors.forename: A
authors.initials: A
authors.lastname: Nakamura
authors.forename: M
authors.initials: M
authors.lastname: Kajimura
authors.forename: H
authors.initials: H
authors.lastname: Sugimura
authors.forename: A
authors.initials: A
authors.lastname: Hishida
authors.forename: T
authors.initials: T
authors.lastname: Ishizaki
mesh_terms: D000368:Aged; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19; D005260:Female; D020022:Genetic Predisposition to Disease; D016481:Helicobacter Infections / Q000453:epidemiology* / Q000235:genetics; D016480:Helicobacter pylori; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D012150:Polymorphism, Restriction Fragment Length; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000453:epidemiology* / Q000235:genetics / Q000382:microbiology
chemical_list: D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19